Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00778232 · ClinicalTrials.gov registry record · NA
Bioequivalence Study of Gabapentin 800 mg Tablets Under Fed Conditions
A NA study, sponsored by Ranbaxy Laboratories Limited.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT00778232: Completed NA study, sponsored by Ranbaxy Laboratories Limited.
NCT00778232 is a NA study that has completed, run by Ranbaxy Laboratories Limited. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00778232, a NA study, has completed, sponsored by Ranbaxy Laboratories Limited.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study compared the relative bioavailability (rate and extent of absorption) of Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited with that of Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd. Distributed by Parke-Davis, division of Warner-Lambert Co. following a single oral dose (1x800 mg tablet) in healthy adult volunteers under non-fasting conditions.
Interventions
- DRUG Gabapentin tablets 800 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2002-10 |
| Est. Completion | 2002-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00778232
The ClinicalTrials.gov registry entry for NCT00778232 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ranbaxy Laboratories Limited, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gabapentin tablets 800 mg is the first listed.
NCT00778232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00778232 about?
NCT00778232 is a clinical study titled "Bioequivalence Study of Gabapentin 800 mg Tablets Under Fed Conditions". This study compared the relative bioavailability (rate and extent of absorption) of Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited with that of Neurontin ® 800 mg tablets of Parke Davis Pharmaceuticals Ltd. Distributed by Parke-Davis, division of Warner-Lambert Co. following a single oral...
What is the current status of trial NCT00778232?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2002-10. Estimated completion is 2002-11.
What interventions are being tested in trial NCT00778232?
The interventions under investigation include: Gabapentin tablets 800 mg (DRUG).
Who is sponsoring clinical trial NCT00778232?
This trial is sponsored by Ranbaxy Laboratories Limited, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.